Stuart Marcus
Founder and CSO
Stuart pioneered the development of Photodynamic Therapy Systems, with over 30 years of experience with ALA.
Mark de Souza
President and CEO
Mark has over 20 years of executive and entrepreneurial experience in the rare disease space.
Nandini Kandolha
CFO
Nandini is an experienced financial and strategic leader with over 15 years of experience in finance, accounting, audit, strategy and team building.
Ely Benaim
CMO and EVP, Development
Ely is a pediatric oncologist with over 25 years of academic and industry experience developing transformative drugs and devices in oncology, including as CMO of Novocure.
Joanne LaValle
Senior Vice President, Regulatory Affairs
Joanne has over 25 years of experience in Regulatory Affairs and Pharmacovigilance focused on drug, device and combination product development and commercialization.
Ramei Sani-Grosso
Senior Vice President, Clinical Operations
Ramei has over 26 years of industry experience in drug development in oncology, rare/orphan disease, and vaccines.
Corina Andresen
VP, Clinical Development
Corina brings more than 24 years of clinical development expertise in pharma/biotech industry, with focus in solid-tumors.
Jacqueline Kuritzky
Senior Director, Clinical Operations
Jacquie has over 30 years of clinical operations experience, including 11 years at Regeneron.
April Freeman
Director, Patient Advocacy & Engagement
April has over 15 years of experience in patient advocacy and public policy.
Sudheer Swamy
Director, Project Management
Sudheer has over 15 years of project leadership experience in biotech and healthcare tech.
Kanthi Gunturi
Assistant Controller
Kanthi has over 15 years of experience in accounting and finance.
Sam Zenhari
Director, Clinical Operations
Sam has over 10 years of experience in drug development in oncology, liver, and rare diseases.
Katrina Lagan
Senior Clinical Trial Manager
Katrina started her career over 20 years ago at UCSF in the HIV ward and has since held past positions at Gilead Sciences, BioMarin, Genentech, Dynavax and Exelixis.
Michael Bellas
Associate Manager, Business Development
Michael graduated from the University of California, Berkeley, where he received a degree in genetics and data science.
Kathryn Rosengrant
Regulatory Affairs Associate
Katie has a background in computer science and has been supporting SonALAsense operations since 2019.
Carolina Brekke
Office Manager
Carolina has over 15 years of experience as an office manager and administrative assistant.
Kat Sampel
Clinical Research Associate
Kat has over 15 years of experience in clinical research trials.
Brian Roden
CMC Advisor
Brian is a research chemist with 25+ years experience in the development of branded and generic pharmaceutical products.
Brian Rogers
Non-Clinical Advisor
Brian has nearly 30 years of industrial toxicology experience, including over 25 years in the biotechnology and pharmaceutical industries.
Chandler Coate
Clinical Trial Assistant
Chandler graduated from the University of California, Berkeley, in 2022 with a degree in Neurobiology.
Sean Corzine
Assistant Manager, IT
Sean has a degree in Computer Science and has a background in data science.
Leading our Mission
SonALAsense is led by an experienced leadership team and Scientific Advisory Board and is the first company to advance sonodynamic therapy into Phase 2 clinical trials. Our leadership has developed multiple drugs and drug-device combination therapies through FDA approval, creating the perfect team to advance Sonodynamic Therapy from bench to bedside. This team has successfully worked together for years, and, in some cases, decades.
Mitchel S. Berger, MD
Professor of Neurological Surgery and Director, Brain Tumor Center, University of California, San Francisco
Pejman Ghanouni, MD, PhD
Associate Professor, Radiology, Stanford University School of Medicine
Stuart L. Marcus, MD, PhD
Founder and Chief Scientific Officer, SonALAsense
Scott R. Plotkin, MD, PhD
Armenise Harvard Professor of Neurology, Harvard Medical School, Chief, Division of Neuro-Oncology, Massachusetts General Hospital
Graeme F. Woodworth, MD
Professor and Chair, Department of Neurosurgery, Director of the Brain Tumor Treatment & Research Center, University of Maryland School of Medicine
Margaret Dugan, MD
CMO, Dracen Pharmaceuticals, Former Senior VP & Global Program Head, Novartis Oncology
Robert Scott, MBBS
Emeritus Professor for Royal College of Ophthalmologists and Defence Medical Services
Stuart L. Marcus, MD, PhD
Founder and CSO
Mark P. de Souza, PhD
President and CEO
Vincent Sai
CEO and Partner, Modality Partnership